Mustafa Özguröğlu, MD, professor of medical oncology, Cerrahpaşa School of Medicine, Istanbul University-Cerrahpaşa, Istanbul, Turkey, discusses the individualization of treatment in non-small cell lung cancer (NSCLC).

NSCLC is a heterogenous disease and each patient with NSCLC is unique, explains Özguröğlu. Moreover, patients have various clinical characteristics, so treatment should be tailored to the individual instead of utilizing a one-size-fits-all approach, Özguröğlu continues.

The phase 3 EMPOWER-Lung1 trial (NCT03088540) enrolled patients with treatment-naïve NSCLC and PD-L1 positivity of 50% or greater. Additionally, patients with treated, clinically stable central nervous system metastases and controlled hepatitis B or C or HIV were eligible for enrollment. 

During the 2021 ASCO Annual Meeting, findings from a subgroup analysis of EMPOWER-Lung1 demonstrated that first-line cemiplimab (Libtayo) improved overall survival, progression-free survival, and overall response rate compared with chemotherapy in patients with advanced NSCLC with PD-L1 positivity of 50% or greater and clinically stable, baseline brain metastases. As such, treatment for this patient population should be tailored to include cemiplimab, Özguröğlu concludes.

Videos

Mustafa Özguröğlu, MD, discusses the individualization of treatment in non-small cell lung cancer.

Mustafa Özguröğlu, MD

Articles

Dr. Ozguroglu on the Individualization of Treatment in NSCLC